Cocaine 2% to 10% · compounded ophthalmic solution
Local Anesthetic
Approved uses
Local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities in adults
40 mg to 160 mg of the 4% solution on cotton or rayon pledgets (each absorbs one mL), a maximum of two pledgets in each nasal cavity, left in place for up to 20 minutes; the total dose for any one procedure should not exceed 3 mg/kg
Its eye-care role, testing for Horner syndrome, is off-label and absent from this label
OFF-LABELNot in the FDA label for this product
Horner syndrome, confirming an oculosympathetic palsy
One drop in each eye, anisocoria read at 40 to 60 minutes; compounded, as no US ophthalmic product is marketed. Strengths of 2% to 10% exist, and strength likely affects response size. With 4% read at 40 minutes in bright light, a post-cocaine anisocoria of 0.8 mm or more caught 29 of 38 unilateral cases (76%; Bremner 2019), so a negative test does not exclude Horner syndrome. Warn that urine may screen positive up to 2 days after 2 drops of 10% per eye at 2001 federal cutoffs, now lower (Jacobson 2001; HHS 2008).
n=169 · 0.8 mm confirms
Cocaine blocks norepinephrine reuptake at the iris dilator, so a pupil with any oculosympathetic lesion dilates less than its fellow and the anisocoria widens. Tested in 119 patients with Horner syndrome against 50 normal subjects, the odds of Horner syndrome rose with the size of the post-cocaine anisocoria: at 0.8 mm the odds ratio was about 1050 to 1, with a lower 95% confidence limit of 37 to 1. The authors also found that simply measuring the anisocoria after cocaine predicted better than calculating the change from baseline. It confirms the diagnosis and says nothing about where the lesion sits. In a 2019 series of 660 consecutive cocaine or apraclonidine tests, the cocaine arm used one drop of 4% read at 40 minutes in bright light; at that strength a post-cocaine anisocoria of 0.8 mm or more caught 29 of 38 unilateral cases (76%), and in normal eyes brown irides dilated less than half as much as blue or green ones (Bremner F. Front Neurol. 2019;10:55, doi 10.3389/fneur.2019.00055). After two drops of 10% in each eye in 50 normal subjects, urine screened positive for the cocaine metabolite benzoylecgonine in 70% at 24 hours, 2% at 48 hours and none at 72 hours on US federal (SAMHSA) workplace assays and cutoffs (Jacobson DM et al. Am J Ophthalmol. 2001;131:742-7, doi 10.1016/s0002-9394(00)00945-4).
Contraindications
Hypersensitivity to cocaine hydrochloride, other ester-based local anesthetics, or any other component of the nasal solution
Compounded ophthalmic solution, strengths vary; FDA product: 4% (40 mg/mL) nasal solution, 4 mL single-use and 10 mL multiple-use bottles
An ester-type local anesthetic that reversibly blocks voltage-gated sodium channels, which prevents conduction in nerve fibers. In the eye-care test it blocks norepinephrine reuptake at sympathetic nerve endings, so a pupil with intact sympathetic supply dilates and a Horner pupil dilates less.
Warnings & Precautions
- Route: the label approves cocaine hydrochloride only as a nasal solution for local anesthesia of the mucous membranes of the nasal cavities, so eye-care use is off-label.
- Corneal sloughing and ulceration: cocaine hydrochloride is for topical use only and is not for injection or ophthalmic use. Cocaine can cause sloughing of the corneal epithelium and should not be used in the eyes. Pitting and ulceration of the cornea has been reported in the literature.
- Abuse and dependence: cocaine is a Schedule II controlled substance with a high potential for abuse.
- Blood pressure and heart rate increases: as reported in the literature, cocaine hydrochloride causes an increase in blood pressure and heart rate; monitor vital signs, including heart rate and rhythm, after administration. Avoid it in patients with a history of myocardial infarction, coronary artery disease, congestive heart failure, irregular heart rhythm, abnormal ECG or uncontrolled hypertension, and in patients with a recent or active history of thyrotoxicosis.
- Myocardial infarction: although not reported in the cocaine hydrochloride clinical trials, myocardial infarction has been reported in the literature and can occur when the drug has been used as recommended.
- Seizures: it has been reported in the literature that cocaine may lower the convulsive threshold. The risk may be higher in patients with a history of seizures or prior EEG abnormalities, but seizures have been reported in patients with no such history. Monitor for seizures.
- Toxicology screening: after the nasal product, cocaine and its metabolites may be detected in plasma for up to one week and in urine for longer than one week, depending on the assay.
- MAO inhibitor toxicity: cocaine hydrochloride may potentiate the effects and toxicity of monoamine-oxidase inhibitors.
- Cocaine toxicity: irreversible plasma cholinesterase inhibitors such as echothiophate may diminish plasma cholinesterase activity, and concomitant administration may increase the risk of cocaine toxicity. Patients with reduced plasma cholinesterase activity may have reduced clearance and increased exposure of plasma cocaine, but the effect may be limited because cocaine is metabolized by multiple enzymes. No dosage adjustment is needed; monitor for clinically-relevant increases in heart rate or blood pressure.
- Myocardial ischemia and ventricular arrhythmias: there are reports in the published literature of myocardial ischemia, myocardial infarction, and ventricular arrhythmias after topical intranasal cocaine was given with epinephrine and phenylephrine during nasal and sinus surgery. Avoid additional vasoconstrictor agents such as epinephrine and phenylephrine with cocaine hydrochloride; if concomitant use is unavoidable, prolonged vital sign and ECG monitoring may be required.
- Increased plasma cocaine exposure: published literature reported that disulfiram treatment increased plasma cocaine exposure by several folds. Avoid cocaine hydrochloride in patients taking disulfiram, and consider using other local anesthesia.
- Excessive stimulation: concurrent use of other central nervous system stimulants with cocaine may result in excessive stimulation, leading to nervousness, irritability, possibly convulsions, or cardiac arrhythmias.
- Cardiovascular adverse reactions: cocaine is a sympathetic neuronal catecholamine reuptake inhibitor, which may potentiate the actions of concomitantly administered sympathomimetic amines. Tricyclic antidepressants may increase the activity of the sympathetic nervous system, which cocaine hydrochloride may also increase, and concomitant use may increase the risk of cardiovascular adverse reactions.
- Hypertension and cardiac arrhythmias: postganglionic blocking agents such as reserpine potentiate cocaine-induced sympathetic stimulation, and concurrent use may increase the risk of hypertension and cardiac arrhythmias that may be life-threatening.
- Hepatic impairment: avoid cocaine, because its clearance has not been evaluated in hepatic impairment and the data are not sufficient to guide dosing.
Common Side Effects
The most common adverse reactions, above 1%, were hypertension, tachycardia and sinus tachycardia.
Pregnancy: There are no available data on cocaine hydrochloride in pregnant women to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Cocaine crosses the placenta by simple diffusion and accumulates in the fetus after repeated use. Chronic cocaine abuse during pregnancy has been associated with adverse maternal and fetal/neonatal outcomes, including reduced fetal growth, but these findings have limited applicability to a single topical exposure. In published animal studies, cocaine given during pregnancy produced hydronephrosis, developmental delays, cerebral hemorrhage, reduced fetal weight and reduced fetal survival at 0.5 to 3.7 times the human reference dose of 37.5 mg, the estimated amount absorbed from the 4% pledgets.
Lactation: Cocaine is present in human milk, although the applicability of these findings to a single topical exposure with limited systemic absorption is unclear. Breastfeeding immediately after a dose could give infant plasma concentrations about half the expected maximum maternal plasma concentration at the 160 mg clinical dose. The effects of that concentration in an infant are unknown, but no level of cocaine exposure is considered safe for a breastfed infant. Infants who ingested cocaine through breast milk have had vomiting, diarrhea, convulsions, hypertension, tachycardia, agitation and irritability. Breastfeeding is not recommended during treatment; advise the patient to pump and discard breast milk for 48 hours after use.
Safety and effectiveness under age 18 have not been established.